Company / SG&A Expense
Nurix Therapeutics, Inc. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$52.7M
FY2025
5-year range
$8.3M / $52.7M
FY2021-FY2025
Trend
+14.8%
vs FY2024
Sector context
#155 of 213
Health Care
What the data says
At $53M, Nurix Therapeutics, Inc.'s sg&a expense ranks #59 of 213 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $8M in FY2021 to $53M in FY2025.
Based on SEC 10-K filings.
$53M in FY2025 with a 5-year CAGR of +26.5%.
Increased from $43M to $53M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +19.1%
- 5-Year CAGR
- +26.5%
- 10-Year CAGR
- -
Sector benchmark
#59 of 213 in Health CareTop 27% of 213This company $52.7M Sector average $722.3M
▼
-92.7% below sector average
Key checks
Key Insights
- Nurix Therapeutics, Inc.'s sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +26.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 14.8% year-over-year.
- Ranks #155 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $52.7M | +14.8% |
| FY2024 | $45.9M | +7.1% |
| FY2023 | $42.9M | +37.5% |
| FY2022 | $31.2M | +274.8% |
| FY2021 | $8.3M | -48.9% |
| FY2020 | $16.3M | +95.9% |
| FY2019 | $8.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026